Patients with osteoporosis who took bisphosphonates, especially risedronate, were at a higher risk of developing acute angle ...

No dedicated clinical trials have compared denosumab and bisphosphonates for fracture prevention in patients on dialysis.

"Among dialysis patients with osteoporosis, denosumab may be more effective than oral bisphosphonates in reducing fracture ...

Long-term bisphosphonate treatment of postmenopausal osteoporosis is associated with reduction of bone turnover and might, therefore, have deleterious adverse effects on the repair of microdamage ...

In the course of evaluating the optimal duration of bisphosphonate treatment the FDA found little benefit of treatment beyond 5 years. [1,2] Moreover, examination of studies where bisphosphonates ...

Denosumab has greater preventive effect on fractures, but increased risk for MACE compared with oral bisphosphonates.

I am an 81-year-old man (5-foot-2 at 122 pounds) in good health, except that I have Type 2 diabetes. My A1C level has been in ...

To determine which parameters, including femur morphology, proximal femur bone mineral density, or patient characteristics, are associated with bisphosphonate-related atypical femur fractures (AFFs) ...

For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on ...

In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...